Tianjin medicine, Shanghai medicine to cooperate!

1. Change of ownership



On December 20, according to Xinhua news, Tianjin Jinlian Investment Holding Co., Ltd. (hereinafter referred to as "Jinlian holding") and Shanghai Industrial Group Co., Ltd. (hereinafter referred to as "Shanghai real estate group") held a signing ceremony for the mixed reform of Tianjin Pharmaceutical Group in Wanli Tianjin Hotel, marking that the mixed reform of Tianjin Pharmaceutical Group has achieved significant results.


It is understood that on September 29, 2020, Tianjin Pharmaceutical mixed reform project was publicly listed in Tianjin property rights trading center, and Tianjin Hushen Biomedical Technology Co., Ltd. won 67% equity of Pharmaceutical Group. In order to participate in the mixed reform of Pharmaceutical Group, Shanghai Shangshi group took the lead in establishing Tianjin Hushen Biomedical Technology Co., Ltd., with a registered capital of 5 billion yuan.


Tianjin Pharmaceutical Group is a large state-owned comprehensive pharmaceutical group, formerly known as Tianjin Pharmaceutical Administration, which was established in 1979. After more than 40 years of development, it has formed five business sectors, integrating scientific research, production and commercial sales. It has established more than 10 joint ventures with GlaxoSmithKline, Otsuka and other multinational well-known pharmaceutical companies, and has been selected as 500 Chinese enterprises for many years Top 100 in China's pharmaceutical industry.


Shanghai real estate group was registered in Hong Kong in July 1981, and is now wholly owned by Shanghai SASAC. Its business covers five areas: medicine and medical treatment, infrastructure and environmental protection, real estate and regional development, consumer goods, financial services and investment. Shanghai real estate group has five domestic and foreign listed companies including Shanghai Pharmaceutical Group Co., Ltd.


The relevant person in charge of the enterprise said that the mixed reform will promote Tianjin Pharmaceutical Group to improve the modern enterprise system and corporate governance structure, enhance the scientific and technological innovation and market-oriented operation ability of Tianjin Pharmaceutical Group, promote Tianjin Pharmaceutical Group to base on its main business and take root in Tianjin, realize transformation and upgrading, and inject "new power" into the development of Tianjin pharmaceutical health industry.



2. Tianjin medicine and Shanghai medicine should cooperate


According to the official website of Tianjin Pharmaceutical, at present, Tianjin Pharmaceutical has more than 180 enterprises, holding three listed companies, namely Zhongxin pharmaceutical, TIANYAO Co., Ltd., Lisheng pharmaceutical and a new third board listed company, Maida technology.


Among them, the group is rich in product resources, producing more than 1300 kinds of products, including traditional Chinese medicine, chemical medicine, biological vaccines, medical devices and other categories. The production capacity of corticosteroid raw materials is among the top in the world, and the production and sales volume of medicinal amino acid raw materials is leading in China. A large number of products, such as Suxiao Jiuxin Pill, shoubishan, Jingwanhong ointment, Tongmai Yangxin pill, youzhuoer, enjoy wide popularity and reputation“ "Big variety" is sold at home and abroad.


In addition, the group also owns six time-honored Chinese brands such as "Darentang", "longshunrong" and "lerentang", and 14 well-known Chinese trademarks such as "Shuangyan", "Songbai" and "Shenghua", ranking first in the national pharmaceutical industry.



Lu Yanchang, Secretary of the Party committee and chairman of Tianjin Pharmaceutical Group, said in an interview with the media: Tianjin Pharmaceutical Group has advantages, but there are many shortcomings in the development. With the development of the enterprise, the existing system and mechanism still restrict the enterprise, such as market development and capital operation.


Shanghai real estate group has a relatively successful experience in the reform of state-owned assets and enterprises and the capital market. In 2008, it carried out asset restructuring of Shanghai Pharmaceutical Group, and now it has produced fruitful results. In the future, the successful experience of Shanghai Pharmaceutical Group will also be applied to Tianjin Pharmaceutical Group.



The above-mentioned people said that in the future, Tianjin Pharmaceutical Group will be integrated into the supply chain of Shanghai pharmaceutical, and the R & D investment of Tianjin Pharmaceutical will be further increased.



This means that in the near future, the two well-known pharmaceutical enterprises will have closer ties and further establish cooperative relations.



3. Mixed mode of reform


In fact, in recent years, promoting the reform of state-owned enterprises has been listed as a key task of the government. Since 2015, the state has issued a number of documents, which have promoted the reform of mixed ownership of pharmaceutical enterprises to a certain extent.


How much impact will this have on the pharmaceutical industry?


According to the statistics of Guoxin Securities, there are 47 state-owned enterprises in A-share pharmaceutical listed companies, 10 central enterprises (National Pharmaceutical Department, China Resources Department, General Department), 33 Local State-owned Enterprises (Shanghai Pharmaceutical Department, TIANYAO department, Taiji department, Harbin Pharmaceutical Department), and 4 school run enterprises (Tsinghua University, Peking University, Zhongda, etc.).


There are different steps for state-owned enterprises to carry out mixed ownership reform: Sinopharm has implemented mixed ownership reform earlier at the subsidiary level, Yunnan Baiyao has introduced private capital and carried out executive compensation reform, while Harbin Pharmaceutical has injected social capital


The pharmaceutical economic daily once wrote an article that the pharmaceutical industry is a field in which private enterprises enter more fully, and state-owned enterprises account for a large proportion of pharmaceutical business. However, pharmaceutical commercial enterprises generally face the problems of long payback period and large capital occupation. The introduction of strategic investment can significantly reduce the company's financial leverage and relieve the pressure of capital operation. Moreover, pharmaceutical commercial enterprises meet the standard of "commercial competitive industry" stipulated by the policy, and are expected to take the lead in the mixed reform. Especially in the circulation enterprises, many commercial companies have the background of state-owned assets, and will have advantages in channels. Based on such advantages and large volume, state-owned assets will go ahead.


The original intention of the pharmaceutical industry lies in the improvement of the efficiency of the social equity structure and the efficiency of the mixed equity market.